Principal Securities Inc. Has $1.74 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Principal Securities Inc. decreased its holdings in Sanofi (NASDAQ:SNY - Free Report) by 19.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,130 shares of the company's stock after selling 8,920 shares during the period. Principal Securities Inc.'s holdings in Sanofi were worth $1,743,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in Sanofi during the 3rd quarter valued at about $29,000. Concord Wealth Partners grew its stake in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Finally, Fortitude Family Office LLC grew its stake in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock valued at $43,000 after buying an additional 659 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ SNY traded up $0.33 on Friday, hitting $54.46. The company's stock had a trading volume of 1,424,158 shares, compared to its average volume of 2,301,609. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a market capitalization of $138.21 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a 50 day moving average of $50.95 and a 200-day moving average of $52.53.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNY. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.